MECTA Corporation - Electroconvulsive Therapy (ECT) Products

Products

spECTrum Devices



		spECTrum Brochure

		Ultrabrief data sheet DOM

		Ultrabrief data sheet INT

Home » Products

MECTA spECTrum ECT Devices

The Newest Standard of Care Available Only From MECTA

The spECTrum 5000 and 4000 models are the fourth generation of MECTA’s ECT devices. They continue to be the most advanced ECT devices technically, while continuing to offer even more safety and effectiveness clinically.

The 5000Q^® and 5000M^™ model devices offer up to five channels of ECG and EEG monitoring, and one Optical Motion Sensor. The 4000Q^™ and 4000M^™ devices are simply the 5000 devices without physiological monitoring capability.

The 5000Q^® and 4000Q^™ offer the user flexibility with four stimulus parameter knobs to control Energy and Charge. The 5000M^™ and 4000M^™ units offer simplicity, with one single Stimulus Intensity knob. This varies Frequency and Duration simultaneously, to control Energy and Charge.
Each spECTrum device is custom manufactured to user specifications according to the Options selected and includes a complete Starter Kit.

Click image to view

Experience Optimized Patient Outcomes with the Newest Dosing Methodologies

No other ECT manufacturer provides a proven evidence based methodology as simple and effective to use as the spECTrum ULTRABRIEF^© (0.3 ms) ECT feature. This feature was designed and tested at Columbia University in the late 1990s, results were reported^46,49 and it was introduced as a feature into MECTA spECTrum ECT devices in July of 2003.

Right unilateral (0.3 ms) ultrabrief six times seizure threshold ECT is equivalent in efficacy to a robust form of bilateral ECT with little sign of cognitive deficit and is simplified by the use of the MECTA spECTrum titration tables. Stimulus dose titration tables are included with each purchase.

No other ECT device implementation of an ultrabrief feature is based on peer reviewed, randomized, double-blind studies. Only spECTrum ULTRABRIEF (0.3 ms) ECT is highly efficient at the lower range, with patients demonstrating seizure thresholds at 5 mC, and can treat the patient across the entire range.

Only MECTA offers hospitals a state of the art ECT device and ultrabrief option that provides the highest benefit by reducing side effects for patients.